CAPR

Capricor Therapeutics, Inc. (CAPR) | Rumor.io

Capricor Therapeutics

CAPR

Attention (50-day avg)0.11%

Attention rank (50-day avg)#88

Bullish sentiment (50-day avg)75%

Price to earnings ratio-3.86

Market capitalization506.4M

Earnings per share-2.45

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-105M

Social

What share of all stock conversation is about CAPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.35% +0.26	0.08% +0.04	0.05% -0.09	0.03% -0.03

Sep 30

The company, Capricor Therapeutics, Inc., has announced a 54% reduction in upper limb function deterioration in a 24-month study for HOPE-3 and OLE, with a clear indication that Deramiocel slows the rate of decline for these patients.
The FDA's "fragility" argument is being disputed, and the agency will have a hard time explaining their reasoning, particularly with the data showing a 54% reduction in upper limb function deterioration.
The company is proceeding with arbitration against NS Pharma, with a favorable outcome expected, and the possibility of a broad label and full revenue stream if the treatment is approved in the next 30-45 days.

Generated by AI

Sentiment

Of the messages about CAPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	79% -1.52	76.04% -7.08	77.25% +3.6	73.85% -7.07
Bearish	21% +1.52	23.96% +7.08	22.75% -3.6	26.15% +7.07

Bullish· Sep 30

The data from the Deramiocel trial shows a 76% reduction in pulmonary function decline, a 66% reduction in decline for the mid-level domain, and a 1.56 point difference in treatment effect, all of which suggest a strong potential for FDA approval.
The FDA's statistical house of cards is about to come crashing down, and the approval of Deramiocel is likely in the next 30-45 days, with a broad label and full revenue stream, which could lead to a significant increase in the company's valuation.
The stock has the potential to reach $50 or higher, with some analysts predicting a price of $12.50+ by the open tomorrow and others estimating the share value to be in the range of $50 or higher if Deramiocel gets approved by the FDA.

Bearish· Sep 29

The stock has been oversold on the daily chart, with an RSI in the 20s, indicating a potential buying opportunity.
Short interest is high, at 37% or 40-50%, which could lead to a short squeeze and a price increase.
The FDA's view on the broader H3 dataset, which includes cardiac outcomes, is extremely negative, which may impact the company's ability to secure a wider label.

Generated by AI

Topics

Of the messages about CAPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Controversies	59.02%	64.96%	17.72%	2.29%
Announcements	0%	7.69%	22.75%	4.07%
Analysts	0%	5.13%	43.95%	42.31%
Technical Analysis	18.03%	9.4%	13.77%	1.6%
Macro	22.95%	12.82%	1.8%	49.39%
Earnings	0%	0%	0%	0.34%

Earnings· Aug 9

Capricor Therapeutics, Inc. (CAPR) reports Q2 2018 financial results, with earnings call to be held on 8/9 after close.
CAPR's stock price dropped 10% since its last earnings report.
CAPR's Q2 earnings call will be streamed live on 8/9 at 4:30pm Eastern.

Analysts· Aug 25

Oppenheimer upgraded Capricor Therapeutics (CAPR) to Outperform with a price target of $54, citing favorable FDA regulatory developments for deramiocel, the company’s treatment for Duchenne muscular dystrophy.
The FDA has accepted materials submitted following last month’s advisory committee meeting as a major amendment and established a new PDUFA action date of November 22.
Analysts are optimistic about the company's prospects, with Oppenheimer's upgrade being seen as a rare, hyper-bullish signal that usually indicates a massive, game-changing piece of news has just been revealed.

Announcements· Aug 24

Capricor Therapeutics has announced an extension of the PDUFA target action date as the FDA continues to review the Deramiocel BLA, with the new date set for November 22, 2026.
The FDA has extended the review period due to a major amendment including new 24-month OLE data and a refined proposed indication focused on upper limb function.
The company is awaiting the FDA's decision on its Duchenne candidate, with the FDA's approval delay potentially affecting the approval process, although the FDA operates on a system funded heavily by industry-paid user fees, allowing it to continue reviewing existing applications.

Controversies· Jul 31

The FDA allegedly never signed SAP 1.1, a draft that was used to exclude data from subjects taking a prohibited drug, and instead used it to include all data, including after the subject started taking the drug.
There are allegations of a regulatory path forward that doesn't involve lawsuits or CRLs, and that the FDA's use of SAP 1.1 was arbitrary and capricious.
The FDA's handling of the CAPR trial has been criticized, with some suggesting that the agency was biased and used the worst SAP to make the statistics and final P values look awful, and that CAPR has a strong case for a lawsuit.

Technical Analysis· Aug 14

The author identifies a potential breakout for $CAPR with a target of $12.00+ and suggests buying above $6.95.
A "big bullflag" pattern is observed in $CAPR, with a double-digit gain on the day, and the author notes a potential double bottom W-pattern.
The author notes a "golden cross" pattern in $CAPR, which could indicate a strong buy signal, and suggests holding up to a new record high.

Generated by AI

Community

Of the messages about CAPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	69.73%	70.72%	64.26%	74.54%
Newcomers	30.27%	29.28%	35.74%	25.46%

Regulars· Sep 30

The latest data posters from WMS 2026 show a 54% reduction in upper limb function deterioration at month 12, and the rate of decline is difficult to dispute, putting the FDA on the defensive.
The arbitration decision is in favor of Capricor, with NS Pharma being heavily favored to win or reach an agreement with Capricor within the next two months, and Capricor proceeding as if they will have to distribute the treatment themselves.
The full data is expected to be on the website on Monday morning, and if the data release is as expected, it could lead to an approval in the next 30-45 days with a broad label and full revenue stream, making it a very easy buy at the current price.

Newcomers· Sep 30

The newcomer investors are expressing strong emotional connections to the company, particularly with regards to its potential to help families affected by Duchenne Muscular Dystrophy (DMD).
The focus is on the company's upcoming FDA meeting and the potential approval of its drug, with some investors predicting a rapid increase in stock price.
There is also discussion about the company's momentum, with some investors speculating about the potential for a "gamma squeeze" or a rapid increase in stock price due to short selling.

Generated by AI

News

Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ)

Capricor (CAPR) spikes on new deramiocel HOPE-3 24-month Duchenne data ahead of Nov.

11h agoSeeking Alpha

Why Did CAPR Stock Jump 20% After-Hours Today?

11h agoYahoo Finance

Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) - Lead Plaintiff Deadline is September 28, 2026

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

5d agoThe Globe and Mail

Kaplan Fox Continues to Remind Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors of the Lead Plaintiff Deadline on September 28, 2026

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

5d agoThe Globe and Mail

SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR

5d agoMorningstar

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky

6d agoMorningstar

Also Discussed

Investors talking about CAPR also mention

#	Name	Attention
1	Candel Therapeutics, Inc.CADL	0.03%+0.02
2	Sarepta Therapeutics, Inc.SRPT	0%-0.01
3	Replimune Group, Inc.REPL	0%0
4	Abivax SAABVX	0.01%-0.01
5	VRNA - Verona Pharma plc	——
6	Regenxbio Inc.RGNX	0%+0
7	Achieve Life Sciences, Inc.ACHV	0%new
8	Aldeyra Therapeutics, Inc.ALDX	0%+0
9	Moleculin Biotech, Inc.MBRX	0%0
10	OmniAb, Inc.OABI	0%new

Capricor Therapeutics, Inc.

Healthcare
Biotechnology

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases. Its lead program, Deramiocel, is an allogeneic cardiac-derived cell therapy being advanced for Duchenne muscular dystrophy, a severe muscle-wasting disorder with significant unmet medical need. The company also develops engineered exosomes through its StealthX platform, which is designed to deliver nucleic acids, proteins, and small molecules for applications in vaccinology and other therapeutic areas. Capricor Therapeutics operates in the healthcare and life sciences sector, where its work spans regenerative medicine, rare-disease treatment, and next-generation biologics. The company’s current portfolio centers on advanced clinical and preclinical programs that aim to address complex conditions through targeted biological mechanisms rather than traditional small-molecule approaches.

Website

Location

10865 Road to the Cure

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about CAPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.35% +0.26	0.08% +0.04	0.05% -0.09	0.03% -0.03

Sep 30

The company, Capricor Therapeutics, Inc., has announced a 54% reduction in upper limb function deterioration in a 24-month study for HOPE-3 and OLE, with a clear indication that Deramiocel slows the rate of decline for these patients.
The FDA's "fragility" argument is being disputed, and the agency will have a hard time explaining their reasoning, particularly with the data showing a 54% reduction in upper limb function deterioration.
The company is proceeding with arbitration against NS Pharma, with a favorable outcome expected, and the possibility of a broad label and full revenue stream if the treatment is approved in the next 30-45 days.

Generated by AI

Sentiment

Of the messages about CAPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	79% -1.52	76.04% -7.08	77.25% +3.6	73.85% -7.07
Bearish	21% +1.52	23.96% +7.08	22.75% -3.6	26.15% +7.07

Bullish· Sep 30

The data from the Deramiocel trial shows a 76% reduction in pulmonary function decline, a 66% reduction in decline for the mid-level domain, and a 1.56 point difference in treatment effect, all of which suggest a strong potential for FDA approval.
The FDA's statistical house of cards is about to come crashing down, and the approval of Deramiocel is likely in the next 30-45 days, with a broad label and full revenue stream, which could lead to a significant increase in the company's valuation.
The stock has the potential to reach $50 or higher, with some analysts predicting a price of $12.50+ by the open tomorrow and others estimating the share value to be in the range of $50 or higher if Deramiocel gets approved by the FDA.

Bearish· Sep 29

The stock has been oversold on the daily chart, with an RSI in the 20s, indicating a potential buying opportunity.
Short interest is high, at 37% or 40-50%, which could lead to a short squeeze and a price increase.
The FDA's view on the broader H3 dataset, which includes cardiac outcomes, is extremely negative, which may impact the company's ability to secure a wider label.

Generated by AI

Topics

Of the messages about CAPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Controversies	59.02%	64.96%	17.72%	2.29%
Announcements	0%	7.69%	22.75%	4.07%
Analysts	0%	5.13%	43.95%	42.31%
Technical Analysis	18.03%	9.4%	13.77%	1.6%
Macro	22.95%	12.82%	1.8%	49.39%
Earnings	0%	0%	0%	0.34%

Earnings· Aug 9

Capricor Therapeutics, Inc. (CAPR) reports Q2 2018 financial results, with earnings call to be held on 8/9 after close.
CAPR's stock price dropped 10% since its last earnings report.
CAPR's Q2 earnings call will be streamed live on 8/9 at 4:30pm Eastern.

Analysts· Aug 25

Oppenheimer upgraded Capricor Therapeutics (CAPR) to Outperform with a price target of $54, citing favorable FDA regulatory developments for deramiocel, the company’s treatment for Duchenne muscular dystrophy.
The FDA has accepted materials submitted following last month’s advisory committee meeting as a major amendment and established a new PDUFA action date of November 22.
Analysts are optimistic about the company's prospects, with Oppenheimer's upgrade being seen as a rare, hyper-bullish signal that usually indicates a massive, game-changing piece of news has just been revealed.

Announcements· Aug 24

Capricor Therapeutics has announced an extension of the PDUFA target action date as the FDA continues to review the Deramiocel BLA, with the new date set for November 22, 2026.
The FDA has extended the review period due to a major amendment including new 24-month OLE data and a refined proposed indication focused on upper limb function.
The company is awaiting the FDA's decision on its Duchenne candidate, with the FDA's approval delay potentially affecting the approval process, although the FDA operates on a system funded heavily by industry-paid user fees, allowing it to continue reviewing existing applications.

Controversies· Jul 31

The FDA allegedly never signed SAP 1.1, a draft that was used to exclude data from subjects taking a prohibited drug, and instead used it to include all data, including after the subject started taking the drug.
There are allegations of a regulatory path forward that doesn't involve lawsuits or CRLs, and that the FDA's use of SAP 1.1 was arbitrary and capricious.
The FDA's handling of the CAPR trial has been criticized, with some suggesting that the agency was biased and used the worst SAP to make the statistics and final P values look awful, and that CAPR has a strong case for a lawsuit.

Technical Analysis· Aug 14

The author identifies a potential breakout for $CAPR with a target of $12.00+ and suggests buying above $6.95.
A "big bullflag" pattern is observed in $CAPR, with a double-digit gain on the day, and the author notes a potential double bottom W-pattern.
The author notes a "golden cross" pattern in $CAPR, which could indicate a strong buy signal, and suggests holding up to a new record high.

Generated by AI

Community

Of the messages about CAPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	69.73%	70.72%	64.26%	74.54%
Newcomers	30.27%	29.28%	35.74%	25.46%

Regulars· Sep 30

The latest data posters from WMS 2026 show a 54% reduction in upper limb function deterioration at month 12, and the rate of decline is difficult to dispute, putting the FDA on the defensive.
The arbitration decision is in favor of Capricor, with NS Pharma being heavily favored to win or reach an agreement with Capricor within the next two months, and Capricor proceeding as if they will have to distribute the treatment themselves.
The full data is expected to be on the website on Monday morning, and if the data release is as expected, it could lead to an approval in the next 30-45 days with a broad label and full revenue stream, making it a very easy buy at the current price.

Newcomers· Sep 30

The newcomer investors are expressing strong emotional connections to the company, particularly with regards to its potential to help families affected by Duchenne Muscular Dystrophy (DMD).
The focus is on the company's upcoming FDA meeting and the potential approval of its drug, with some investors predicting a rapid increase in stock price.
There is also discussion about the company's momentum, with some investors speculating about the potential for a "gamma squeeze" or a rapid increase in stock price due to short selling.

Generated by AI

Capricor Therapeutics

Social

Sep 30

Bullish· Sep 30

Bearish· Sep 29

Earnings· Aug 9

Analysts· Aug 25

Announcements· Aug 24

Controversies· Jul 31

Technical Analysis· Aug 14

Regulars· Sep 30

Newcomers· Sep 30

Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ)

Why Did CAPR Stock Jump 20% After-Hours Today?

Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) - Lead Plaintiff Deadline is September 28, 2026

Kaplan Fox Continues to Remind Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors of the Lead Plaintiff Deadline on September 28, 2026

SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky

Also Discussed

Capricor Therapeutics, Inc.

Company Information

Location

Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ)

Why Did CAPR Stock Jump 20% After-Hours Today?

Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) - Lead Plaintiff Deadline is September 28, 2026

Kaplan Fox Continues to Remind Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors of the Lead Plaintiff Deadline on September 28, 2026

SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky

Also Discussed

Social

Sep 30

Bullish· Sep 30

Bearish· Sep 29

Earnings· Aug 9

Analysts· Aug 25

Announcements· Aug 24

Controversies· Jul 31

Technical Analysis· Aug 14

Regulars· Sep 30

Newcomers· Sep 30